Assessment of fatigue and its impact in chronic liver disease

Younossi, Zobair M.; Kremer, Andreas E.; Swain, Mark G.; Jones, David; Bowlus, Christopher; Trauner, Michael; Henry, Linda; Gerber, Lynn

doi:10.1016/j.jhep.2024.04.008

Journal of Hepatology

2024

DOI: 10.1016/j.jhep.2024.04.008

|View full text |Cite

Assessment of fatigue and its impact in chronic liver disease

Zobair M. Younossi,

Andreas E. Kremer,

Mark G. Swain

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Fatigue is a symptom of clinical importance in patients with primary sclerosing cholangitis (SOMA.LIV)

Hartl,

Buck,

Löwe

et al. 2025

Journal of Hepatology

View full text Add to dashboard Cite

Fatigue is a symptom of clinical importance in patients with primary sclerosing cholangitis (SOMA.LIV)

Hartl,

Buck,

Löwe

et al. 2025

Journal of Hepatology

View full text Add to dashboard Cite

Reply to: “Fatigue is a symptom of clinical importance in patients with primary sclerosing cholangitis (SOMA.LIV)”

Henry,

Younossi

2025

Journal of Hepatology

View full text Add to dashboard Cite

Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Barberá,

White,

Arora

et al. 2024

Semin Liver Dis

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and can progress to serious complications, including metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Predisposing risk factors for MASH include obesity, type 2 diabetes, dyslipidemia, and metabolic syndrome. Patients with MASH often experience significant impairments in their health-related quality of life (HRQoL) and other patient-reported outcomes (PROs), particularly in physical functioning domains. Incorporating PROs offers valuable insights into patients' perspectives on their symptoms, treatment efficacy, and overall well-being, thereby guiding more holistic and patient-centered care strategies. This review aims to investigate the utilization of patient-reported outcome measures (PROMs) in the context of MASLD and MASH care, identify which PROMs are employed, and summarize the outcomes reported.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Assessment of fatigue and its impact in chronic liver disease

Cited by 6 publications

References 119 publications

Fatigue is a symptom of clinical importance in patients with primary sclerosing cholangitis (SOMA.LIV)

Fatigue is a symptom of clinical importance in patients with primary sclerosing cholangitis (SOMA.LIV)

Reply to: “Fatigue is a symptom of clinical importance in patients with primary sclerosing cholangitis (SOMA.LIV)”

Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Contact Info

Product

Resources

About